
Brian Drachman
21 posts

Brian Drachman
@philimd
Cardiologist at Penn Presbyterian Medical Center, Philadelphia, PA












@maz_hanna @MarthaGrogan1 @BrettSperryMD @Amyloidosis_ARC A real risk- on tafamidis trial, were multiple steps to ensure no misdiagnosed AL pts were treated- in the flood of PYP scans being done, there is real risk of AL patients getting funneled towards tafamidis. Patients should ideally all get at least looked at in amyloid centers.


@afshinfarzan @Ron_Witteles @hvanspall @AmitRPatelMD @vass_vassiliou @purviparwani @iamritu @IAmDrIbrahim @MarthaGrogan1 @cshenoy3 Not to add insult to injury, but limitations of sFLC: “Using the conventional κ/λ ratio, 36.4% of the ratios were abnormal, in the absence of monoclonal gammopathy.” academic.oup.com/ajcp/article/1…


